SCHEMBL23218780

SCHEMBL23218780

CCOC(=O)Cc1ccc(OC)cc1OCc1c2cc(-c3cccc(CN)c3)ccc2nn1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 4/20 0.48
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PLG P00747 2/20 0.40
PLAU P00749 2/20 0.40
F11 P03951 1/20 0.40
KLKB1 P03952 1/20 0.40
F7 P08709 1/20 0.40
TPSB2 P20231 1/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
P2RX3 P56373 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2D6 P10635 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852485 1.00 CFD (0.48) CFDALDH1A1KDM4EHPGDGLA
SCHEMBL23218475 0.91 CFD (0.49) CFDALDH1A1KDM4EHPGDMAPT
SCHEMBL29852628 0.91 CFD (0.49) CFDALDH1A1KDM4EHPGDMAPT
SCHEMBL29592902 0.91 CFD (0.50) CFDALDH1A1PLGPLAUF11
SCHEMBL23218972 0.91 CFD (0.50) CFDALDH1A1PLGPLAUF11
SCHEMBL23218411 0.91 CFD (0.46) CFDALDH1A1KDM4EHPGDGLA
SCHEMBL29852920 0.91 CFD (0.46) CFDALDH1A1KDM4EHPGDGLA
SCHEMBL23218692 0.89 CFD (0.59) CFDALDH1A1KDM4EHPGDMAPT
SCHEMBL29852638 0.89 CFD (0.59) CFDALDH1A1KDM4EHPGDMAPT
SCHEMBL23218829 0.87 CFD (0.52) CFDALDH1A1KDM4EHPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885ALDH1A1 2667/4885KDM4E 4172/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885ALDH1A1 3142/4885KDM4E 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.